Literature DB >> 20422564

A comparison of different orbivirus proteins that could affect virulence and pathogenesis.

H Huismans1, V van Staden, W C Fick, M van Niekerk, T L Meiring.   

Abstract

The factors that determine the virulence and pathogenesis characteristics of bluetongue virus (BTV), African horse sickness virus (AHSV) and other orbiviruses are not well known. With respect to the viral proteins that are expected to play a role it may be assumed that proteins, such as the outer capsid proteins VP2 and VP5, that are involved in the attachment of virus particles to target cells and influence replication efficiency are particularly important. Equally important are viral proteins such as non-structural protein NS3 that influence the release of virus particles from a target host or vector cell. The authors compare the amino acid sequence variation, structural motifs and some phenotypic characteristics of proteins VP2, VP5 and NS3 of different orbiviruses, such as AHSV, BTV and equine encephalosis virus (EEV). The most variable protein is VP2 and a pair-wise alignment of VP2 sequences of different serotypes of both BTV and AHSV indicated variation of between 48% to 64% and 46% to 52% for most isolates, respectively. Several regions of high variability can be identified. VP5 of BTV is much less variable than VP2 but still more so than the cognate AHSV VP5. In contrast, the NS3 protein of AHSV is much more variable than its BTV or EEV counterpart with maximum levels of NS3 variation up to 36% as compared to 10% for BTV. The AHSV NS3 variation is clustered into three discreet phylogenetic groups. All orbivirus NS3/NS3A proteins share a number of highly conserved structural features that include two hydrophobic domains (HD1 and HD2) that are involved in the interaction with the membrane. Most of the NS3 variation is located in HD1 and the adjacent variable region between HD1 and HD2. In the case of AHSV this region only has 13% identity compared to 64% in the case of BTV. NS3 of AHSV is also a highly toxic protein and mutation analysis has indicated that the toxicity is associated with the two hydrophobic domains. Expression of NS3 deletion mutants in bacterial cells has shown that both HD1 and HD2 are necessary for cytotoxicity and that removal of the adjacent N-terminal domains increases cytotoxicity. Preliminary results with different AHSV strains and the corresponding NS3 equivalent have indicated that the membrane permeabilisation effect of the individual NS3 proteins correlate with the permeabilisation effect of the corresponding viruses. These results would suggest that characterisation of the NS3 protein by itself might predict some phenotypic characteristics and potential membrane destabilisation effect of the corresponding virus.

Entities:  

Year:  2004        PMID: 20422564

Source DB:  PubMed          Journal:  Vet Ital        ISSN: 0505-401X            Impact factor:   1.101


  11 in total

1.  A coiled-coil motif in non-structural protein 3 (NS3) of bluetongue virus forms an oligomer.

Authors:  Nirmal Chacko; Nihar Nalini Mohanty; Sanchay Kumar Biswas; Karam Chand; Revanaiah Yogisharadhya; Awadh Bihari Pandey; Bimalendu Mondal; Sathish Bhadravati Shivachandra
Journal:  Virus Genes       Date:  2015-08-30       Impact factor: 2.332

2.  Genomic analysis of putative novel serotypes of Tibet orbivirus isolated in Japan.

Authors:  Yuto Suda; Katsunori Murota; Hiroaki Shirafuji; Tohru Yanase
Journal:  Arch Virol       Date:  2021-02-06       Impact factor: 2.574

3.  Novel Function of Bluetongue Virus NS3 Protein in Regulation of the MAPK/ERK Signaling Pathway.

Authors:  Damien Vitour; Grégory Caignard; Cindy Kundlacz; Marie Pourcelot; Aurore Fablet; Rayane Amaral Da Silva Moraes; Thibaut Léger; Bastien Morlet; Cyril Viarouge; Corinne Sailleau; Mathilde Turpaud; Axel Gorlier; Emmanuel Breard; Sylvie Lecollinet; Piet A van Rijn; Stephan Zientara
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

4.  Complete genome characterisation of a novel 26th bluetongue virus serotype from Kuwait.

Authors:  Sushila Maan; Narender S Maan; Kyriaki Nomikou; Eva Veronesi; Katarzyna Bachanek-Bankowska; Manjunatha N Belaganahalli; Houssam Attoui; Peter P C Mertens
Journal:  PLoS One       Date:  2011-10-21       Impact factor: 3.240

5.  The effect of glycosylation on cytotoxicity of Ibaraki virus nonstructural protein NS3.

Authors:  Maho Urata; Rie Watanabe; Hiroyuki Iwata
Journal:  J Vet Med Sci       Date:  2015-07-16       Impact factor: 1.267

6.  Identification of the Genome Segments of Bluetongue Virus Serotype 26 (Isolate KUW2010/02) that Restrict Replication in a Culicoides sonorensis Cell Line (KC Cells).

Authors:  Gillian D Pullinger; Marc Guimerà Busquets; Kyriaki Nomikou; Mark Boyce; Houssam Attoui; Peter P Mertens
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

7.  Isolation of Tibet orbivirus from Culicoides and associated infections in livestock in Yunnan, China.

Authors:  Jinglin Wang; Huachun Li; Yuwen He; Yang Zhou; Aiguo Xin; Defang Liao; Jinxin Meng
Journal:  Virol J       Date:  2017-06-08       Impact factor: 4.099

8.  B-cell epitopes of African horse sickness virus serotype 4 recognised by immune horse sera.

Authors:  Evans M Mathebula; Frederika E Faber; Wouter Van Wyngaardt; Antoinette Van Schalkwyk; Alri Pretorius; Jeanni Fehrsen
Journal:  Onderstepoort J Vet Res       Date:  2017-02-24       Impact factor: 1.792

9.  African Horse Sickness Caused by Genome Reassortment and Reversion to Virulence of Live, Attenuated Vaccine Viruses, South Africa, 2004-2014.

Authors:  Camilla T Weyer; John D Grewar; Phillippa Burger; Esthea Rossouw; Carina Lourens; Christopher Joone; Misha le Grange; Peter Coetzee; Estelle Venter; Darren P Martin; N James MacLachlan; Alan J Guthrie
Journal:  Emerg Infect Dis       Date:  2016-12-15       Impact factor: 6.883

Review 10.  A review of experimental infections with bluetongue virus in the mammalian host.

Authors:  Peter Coetzee; Moritz van Vuuren; Estelle H Venter; Maria Stokstad
Journal:  Virus Res       Date:  2014-01-24       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.